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Cytomegalovirus (CMV) replication after allogeneic hematopoietic stem cell transplantation (HSCT) was
historically associated with increased nonrelapse mortality (NRM). More recently, different groups have re-
ported an association between CMV replication and reduced risk of acute myeloid leukemia (AML) relapse.
Given the conﬂicting results, we evaluated the impact of CMV replication and other covariates on the
outcome of a retrospective cohort of 265 adults with B cell lymphoma receiving allogeneic HSCT from HLA-
identical siblings or alternative donors. In time-dependent multivariate analysis, CMV replication, evaluated
by pp65 antigenemia, had no independent effect on the risk of relapse (hazard ratio [HR], 1.0; 95% conﬁdence
interval [CI], .6 to 1.6; P ¼ .9), although it was associated with a reduced overall survival (HR, 2.0; 95% CI, 1.3 to
3.2; P ¼ .001) and an increased NRM (HR, 2.5; 95% CI, 1.1 to 5.3; P ¼ .01). Consistently, donor and/or recipient
CMV seropositivity were not associated with a different outcome relative to CMV double-negative serostatus.
In multivariate models, a diagnosis of follicular lymphoma (P < .0001) and pretransplantation complete
remission status (P < .0001) were the main independent predictors for improved relapse-free survival. In
summary, contrary to what is observed in patients with AML, this report identiﬁes no independent role for
CMV replication or serostatus on the relapse of patients with B cell lymphomas undergoing allogeneic HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Patients with lymphoid malignancies who relapse after
second-line chemotherapy or autologous transplantation
have a dismal prognosis and very few effective options for
salvage treatment. Allogeneic hematopoietic stem cell trans-
plantation (HSCT) after myeloablative (MAC) or reduced-
intensity conditionings (RIC) is the only potential curative
strategy for patients with recurrent indolent or aggressive
non-Hodgkin’s (NHL) and Hodgkin’s lymphomas (HL) [1,2].
In a prospective trial for lymphoma patients [3], we have
previously identiﬁed lymphoma histotype and pre-
transplantation disease status as the main independentdgments on page 889.
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14.02.015variables affecting the risk of disease relapse and post-
transplantation outcome. More recently, human cytomega-
lovirus (CMV) replicationwas found to be associated not only
with higher post-HSCT nonrelapse mortality (NRM) [4], but
also with a reduced risk of relapse for patients with acute
myeloid leukemia (AML) [5]. This observation, in line with
previous reports on the effect of CMV replication and
serostatus on the outcome of patients with AML [6-8], was
not conﬁrmed in a recent retrospective analysis of subjects
with other myeloid and lymphoid malignancies who un-
derwent transplantation [9].
Given the conﬂicting results, we analyzed a retrospective
cohort of 265 B cell lymphoma patients receiving allogeneic
HSCT from HLA-identical siblings or alternative donors to
investigate the potential role of post-HSCT CMV replication
and pre-HSCT CMV serostatus on transplantation outcome.PATIENTS AND METHODS
Study Design
This is a retrospective study including 265 consecutive adult B cell
lymphoma patients who underwent transplantation in any 1 of 7 Italian
institutions between April 1998 and November 2012. The institutional
Table 1
Patients Characteristics According to Post-transplantation pp65 Antigenemia
Characteristics All Patients Patients with
pp65-Antigenemia
Patients without
pp65-Antigenemia
P Value
Patients, n 265 133 (50%) 132 (50%)
Histologic Subtype
Follicular non-Hodgkin lymphoma 63 (20%) 37 (57%) 27 (43%)
Aggressive non-Hodgkin lymphoma 94 (31%) 46 (49%) 48 (51%) .3
Chronic lymphocytic leukemia 22 (7%) 13 (59%) 9 (41%)
Hodgkin lymphoma 84 (27%) 37 (44%) 47 (56%)
Patient age, median (range), yr 45 (18-68) .2
<40 101 (38%) 46 (45%) 55 (55%)
40 164 (62%) 88 (53%) 76 (47%)
Donor type .003
Sibling 139 (52%) 58 (42%) 81 (58%)
Alternative 126 (48%) 76 (60%) 50 (40%)
Immunosuppression .03
CSA/MTX 141 (55%) 62 (43%) 79 (57%)
ATG or alemtuzumab 124 (45%) 71 (57%) 53 (43%)
Donor/patient CMV serostatus <.0001
Negative/Negative 28 (12%) 1 (3%) 27 (97%)
Others 237 (88%) 132 (55%) 105 (45%)
Disease status at HSCT .2
CR 108 (41%) 61 (56%) 47 (44%)
PR 92 (36%) 43 (47%) 49 (53%)
Refractory (SD/PD) 65 (23%) 30 (46%) 35 (54%)
Number of lines of CT 1
2 68 (26%) 34 (50%) 34 (50%)
>2 197 (74%) 99 (50%) 98 (50%)
Preparative regimen .1
MAC 75 (26%) 43 (57%) 32 (43%)
RIC 189 (74%) 90 (47%) 99 (53%)
Graft source .6
PBSC 239 (92%) 122 (51%) 117 (49%)
BM 26 (18%) 12 (46%) 14 (54%)
aGVHD
No 134 (51%) 64 (48%) 68 (52%) .5
Yes 131 (49%) 69 (52%) 62 (48%)
Grade I-II 104 51 (49%) 53 (51%) .6
Grade III-IV 27 15 (55%) 12 (45%)
cGVHD 1
No 169 (65%) 66 (51%) 64 (49%)
Yes 96 (35%) 48 (50%) 48 (50%)
Mild 36 17 (47%) 19 (53%) .5
Moderate 32 15 (47%) 17 (53%)
Severe 27 16 (59%) 11 (41%)
CR indicates complete remission; PR, partial remission; SD/PD, stable disease/progressive disease; MAC, myeloablative conditioning; RIC, reduced-intensity
conditioning; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; CT, chemo-
therapy; CMV, cytomegalovirus; CSA, cyclosporine; MTX, methotrexate; ATG, antithymocyte globulin.
P value with Fisher’s test.
Bold indicates signiﬁcant P values.
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encompasses all subjects with lymphoma who received allogeneic HSCT at
the fore-mentioned institutions fulﬁlling the following criteria: (1) graft
source represented by an HLA-identical sibling or an alternative (matched
unrelated donor or unmatched sibling, excluding haploidentical relatives)
donor; (2) availability of complete information about HLA matching be-
tween donor and recipient at the HLA loci A, B, C, DRB1, and DQB1, through
high-resolution genotyping (previously described [10]); (3) availability of
pretransplantationeCMV antibody serological status of both donor and
recipient; (4) availability of CMV-seronegative donors of blood product
substitutions for patients and donors pairs with pretransplantation-
negative CMV status; (5) regularly monitored, once or twice weekly, CMV
replication by pp65-antigenemia until at least week 16 after trans-
plantation; (6) no use of prophylactic donor lymphocyte infusion; and (7)
conﬁrmed histologic diagnosis of B cell NHL or HL. Patients with T cell
lymphomas were not included, given their different outcome.Transplantation Characteristics
The pretransplantation conditioning regimen consisted of the combi-
nation of thiotepa, either at 15 mg/kg (myeloablative) or 10 mg/kg (reduced
intensity) and cyclophosphamide 60 mg/kg plus ﬂudarabine 60 mg/m2 in
most patients (n ¼ 159), as previously described [11]; thiotepa-
cyclophosphamide plus melphalan 70 mg/m2 in 11 subjects; and thiotepa-
cyclophosphamide in 30 patients [12]. Other conditioning regimens weremelphalan 140 mg/m2 plus ﬂudarabine 60 mg/m2 in 13 subjects and the
combination of low-dose total body irradiation with chemotherapy in the
remaining 51 subjects [13]. Pharmacological prophylaxis of acute graft-
versus-host disease (GVHD) consisted of oral cyclosporine and short-
course methotrexate for the 139 patients who underwent transplantation
from an identical sibling. One-hundred twenty-six patients received a graft
from an alternative donor (8 from a mismatched sibling, 50 from an HLA-
matched unrelated donor (MUD), and 68 from a mismatched MUD): these
patients received further immunosuppression, either with antithymocyte
globulin (ATG, Thymoglobulin, Genzyme, Europe BV, Naarden, The
Netherlands) 7 mg/kg total dose on days -4 and -3 before transplantation
(92 subjects) or with alemtuzumab 15 to 30 mg/m2 (30 subjects), as pre-
viously published [13-15]. Mismatched donors comprised both antigen- or
allele-mismatched transplantations at loci HLA-A, -B, -C, -DR, or -DP.
Pretransplantation disease status and response were evaluated by
computed tomography or positron emission tomography and assessed ac-
cording to criteria established by Cheson et al. [16]. Acute and late acute
GVHD [17] and chronic or early chronic GVHD were diagnosed as previously
described [18].CMV Antigenemia and Pre-Emptive Therapy
CMV replication was detected by pp65-antigenemia positivity. Moni-
toring started when a white blood cell count of 500 per microliter was
reached after HSCT and continued until week 16 [19]. CMV replication was
Table 2
Variables Inﬂuencing Five-Year Cumulative Incidence of Relapse, Overall Survival, and Nonrelapse Mortality in Univariate Analysis*
Characteristics Cumulative Incidence
of Relapse (95% CI)
P Valuey P Adjustedx OS (%)
(95% CI)
P Valuez P Adjustedx NRM (%)
(95% CI)
P Valuez P Adjustedx
Histologic Subtype .2 1.0000
Follicular non-Hodgkin lymphoma 14 (6-24) <.001 .0014 66 (54-88) .02 .2800 28 (16-40)
Aggressive non-Hodgkin lymphoma 48 (37-58) 41 (31-51) 25 (15-36)
Chronic lymphocytic leukemia 48 (25-69) 52 (31-74) 37 (15-59)
Hodgkin lymphoma 52 (41-63) 53 (40-66) 18 (8-28)
Age .3 1.0000
<40 54 (44-63) .0008 .0112 42 (31-53) .2 1.0000 21 (12-30)
40 34 (27-42) 57 (50-65) 27 (20-35)
Donor type .2 1.0000
HLA-identical Sibling 42 (34-50) .7 1.0000 57 (49-66) .03 .4200 21 (14-28)
Alternative 42 (32-51) 44 (34-54) 28 (19-38)
Immunosuppression .04 .5600
CSA/MTX 43 (35-51) .5 1.0000 57 (49-66) .03 .4200 19 (12-27)
ATG or alemtuzumab 41 (31-50) 45 (35-55) 31 (22-40)
Donor/patient CMV serostatus .1 1.0000
Negative/negative 55 (34-72) .1 1.0000 56 (23-79) .2 1.0000 12 (0-23)
Others 40 (34-47) 51 (44-58) 26 (20-32)
CMV reactivation .2 1.0000
Yes 34 (25-42) .03 .4200 48 (39-57) .2 1.0000 30 (21-39)
No 50 (41-58) 56 (47-65) 19 (12-26)
Disease status at HSCT .3 1.0000
CR 30 (21-40) £.0001 .0014 65 (55-75) <.0001 .0014 21 (13-29)
PR 43 (33-54) 54 (43-65) 25 (16-35)
Refractory (SD/PD) 59 (46-70) 25 (14-36) 34 (17-51)
aGVHD
No 45 (36-54) .2 1.0000 59 (50-68) .06 .8400 18 (11-26) .03 .4200
Yes 38 (29-47) 45 (36-54) 31 (22-40)
Grade I-II 45 (34-55) .01 .1400 52 (42-62) £.0001 .0014 23 (14-32) £.0001 .0014
Grade III-IV 18 (6-34) 20 (5-35) 60 (51-79)
cGVHD
No 45 (37-53) .2 1.0000 48 (40-56) .01 .1400 25 (18-32) .1 1.0000
Yes 37 (27-47) 59 (49-69) 21 (12-30)
Mild 35 (20-50) .9 1.0000 75 (62-89) .01 .1400 5 (0-12) .0008 .0112
Moderate 42 (23-60) 59 (39-79) 15 (0-32)
Severe 36 (18-53) 38 (20-56) 48 (28-68)
OS indicates overall survival; NRM, nonrelapse mortality; CR, complete remission; PR, partial remission; SD/PD, stable disease/progressive disease; MAC,
myeloablative conditioning; RIC, reduced-intensity conditioning; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HSCT,
hematopoietic stem cell transplant; CT, chemotherapy; CI, conﬁdent interval; CMV, cytomegalovirus; CSA, cyclosporine, MTX, methotrexate.
Bold indicates signiﬁcant P values.
* Only variables with a signiﬁcant P values are shown, for variables analyzed see material and methods.
y P value with Gray test.
z P value with log-rank test.
x P adjusted value with Bonferroni method.
J. Mariotti et al. / Biol Blood Marrow Transplant 20 (2014) 881e903 887assumed if at least 5 CMV pp65 antigen-positive cells per 5  105 white
blood cells were detected at 2 consecutive time points. All patients received
acyclovir prophylaxis up to 1 year after transplantation. In all patients, CMV
pre-emptive treatment consisted of ganciclovir 5 mg/kg twice each day or
foscarnet 90 mg/kg twice each day [20], until the ﬁrst negative antigenemia
sample, followed by maintenance treatment for the subsequent 2 weeks.
Statistical Analysis
Univariate overall survival (OS) and nonrelapse mortality (NRM) were
calculated with Kaplan-Meier method and groups were compared with log-
rank test. Cumulative incidence method and groups were compared with
Gray’s test to evaluate the variables for relapse, treating death in remission
as a competing event. Multiple univariate comparisons were adjusted with
the Bonferroni method. The multivariate analysis was done with the Cox
model to evaluate risk factors for relapse, NRM, andmortality. The covariates
were chosen by the clinicians, based on clinical relevance on the prognosis
after transplantation. All the covariates were entered in the model in 1
single step (“enter” method). CMV replication after transplantation, acute
GVHD, and chronic GVHD were considered as time-dependent covariates.
The other variables included, both for univariate and multivariate analysis,
were pretransplantation disease status (complete remission [CR], partial
remission, and refractory disease, including stable and progressive disease),
lymphoma histology (follicular and aggressive NHL, chronic lymphocytic
leukemia, and HL), ex vivo T cell depletion, graft source (peripheral blood
versus bone marrow), intensity of the conditioning regimen (RIC versus
MAC), and pretransplantation donor-recipient CMV serostatus (donor-
recipient double negative or positivity of the donor and/or recipient). The
analysis was done with R software version (Ultima, Wien, Austria) (package
survival).RESULTS
Patient Characteristics
The cohort included a total of 265 patients with B cell
lymphoma, 181 with NHL, and 84 with HL. Patient charac-
teristics relative to CMV replication are summarized in
Table 1. Pp65-antigenemia positivity occurred in 133 patients
(50%) at a median of 34 days after allogeneic HSCT, with 90%
of reactivation diagnosed before day 100. Patients with and
without CMV replication were similar relative to histologic
subtype, graft source, age, number of pretransplantation
chemotherapy lines, pretransplantation disease status, and
onset of acute or chronic GVHD. As predicted, CMV replica-
tion occurred more frequently in patients who had a positive
donor or recipient CMV serostatus (P < .0001), and in those
who underwent transplantation from an alternative donor
(P¼ .003), receiving a more potent immunosuppressionwith
in vivo T cell depletion (P ¼ .03).
Risk of Relapse
With a median follow-up of 814 days (range, 6 to 5727),
107 of 265 (40%) patients experienced disease relapse or
progression at a median of 185 days (range, 21 to 1980) after
transplantation. The 5-year cumulative incidence of relapse
was 42%. The main variables associated with a reduced 5-year
J. Mariotti et al. / Biol Blood Marrow Transplant 20 (2014) 881e903888cumulative incidence of relapse were the following: having
follicular lymphoma, being in CR before transplantation,
having post-HSCT CMV replication, and being older than
40 years (Table 2). This last variablewas related to the fact that
follicular lymphoma was more frequent after 40 years of age
(P < .0001). Of note, when multiple univariate comparisons
were adjusted with the Bonferroni method, CMV replication
was no longer associated with a reduced incidence of relapse
(Table 2). In the time-dependent multivariate analysis, neither
CMV replication nor CMV seropositivity were independent
predictors for the risk of relapse (hazard ratio [HR], 1.0; 95%
conﬁdence interval [CI], .6 to 1.6; P¼ .9 and HR, .8, 95% CI, .4 to
1.6; P ¼ .6, respectively) (Table 3). On the contrary, lymphoma
subtype and pretransplantation disease status remained in-
dependent variables affecting disease relapse: HL, aggressive
NHL, and chronic lymphocytic leukemia had higher relapse
rates relative to follicular lymphomas and, similarly, patients
with persistent disease relative to those in CR (Table 3).Overall Survival and Nonrelapse Mortality
At the last follow-up, 125 patients had died, 65 with active
disease and 60 because of NRM. Five-year OS and NRM were
52% and 25%, respectively. In univariate analysis, CMV repli-
cation and CMV serostatus were not associated with different
OS or NRM rates. Of note, CR status, follicular NHL, and the
occurrence of chronic GVHD were associated with a higher
chance of survival (Table 2). In addition, patients receiving
in vivo T cell depletion with ATG or alemtuzumab, those who
underwent transplantation from an alternative donor, and
thosedeveloping grade III to IV acuteGVHDand severe chronic
GVHD had a lower OS because of a higher NRM rate (Table 2).
Whenmultipleunivariate comparisonswereadjustedwith the
Bonferroni method, only pretransplantation disease status,
grade III to IV acute GHVD, and severe chronic GVHD were
associated with different OS and NRM rates (Table 2). In time-
dependent multivariate analysis, pretransplantation disease
status was the main variable affecting mortality, as patients
with refractory disease had roughly a 4-fold risk of death
compared with those in CR (Table 3). Moreover, CMV replica-
tion was associated with a lower chance of survival (HR, 2.0;
95% CI,1.3 to 3.2; P¼ .001) and an increased NRM rate (HR, 2.5;
95% CI, 1.1 to 5.3; P ¼ .01) (Table 3).Table 3
Variables Inﬂuencing the Risk of Relapse, Mortality and Nonrelapse Mortality in M
Covariate Risk of Relapse
HR (95% CI) P Value
Diagnosis
Follicular non-Hodgkin lymphoma 1
Aggressive B cell lymphoma 6.0 (2.5-14.3) <.0001
Hodgkin lymphoma 5.0 (2.0-12.2) .0003
CLL 4.7 (1.7-13.1) .002
Pretransplantation Disease Status
CR 1
PR 2.4 (1.4-4.1) .006
Refractory
SD 2.1 (.9-4.8) .07
PD 5.2 (2.8-9.5) <.0001
CMV replication after HSCT 1.0 (.6-1.6) .9
CMV serostatus (D/R positive versus DN) .8 (.4-1.6) .6
Acute GVHD .6 (.4-1.0) .1
Chronic GVHD 1.1 (.6-1.9) .6
CLL indicates chronic lymphocytic leukemia; CR, complete remission; PR, partial
plantation; D/R, donor and/or recipient; DN, double negative; ATG, antithymocyte
marrow; HR, hazard ratio; CI, conﬁdence interval; NRM, nonrelapse mortality.
Only variables with a signiﬁcant P values are shown; for variables analyzed, see m
Bold indicates signiﬁcant P values.Effect of pp65-antigenemia on Speciﬁc Subtypes
Recent reports suggested that the antitumor effect asso-
ciated with CMV replication might be mediated by the donor
immune system activated by the viral infection [21,22]. We,
therefore, performed subsequent analysis in a subgroup of
patients who were more likely to beneﬁt from the immune-
mediated antitumor effectdthose receiving transplants from
an HLA-identical sibling, and, therefore, not treated with
in vivo T cell depletion.
We found that CMV replication, together with follicular
lymphoma histology, pretransplantation CR status, acute and
chronic GVHD, was associated with a lower 5-year cumula-
tive incidence of relapse (Supplementary Table 1). Disease
status and histologic subtype were the main factors affecting
OS, whereas acute GVHD and severe chronic GVHD were the
only variables associated with a higher NRM (Supplementary
Table 2). Again, when multiple univariate comparisons were
adjusted with the Bonferroni method, only lymphoma his-
tology, pretransplantation disease status, and grade III to IV
acute GVHD retained a signiﬁcant effect on outcome
(Supplementary Table 1). In the time-dependent multivar-
iate analysis, CMV replication and serostatus were not in-
dependent factors for the risk of relapse (HR, .5 and 2.3,
respectively) (Supplementary Table 2). A diagnosis of follic-
ular NHL was an independent predictor of reduced relapse
risk, whereas pretransplantation CR status and a peripheral
blood donor graft were both associated with reduced chance
of relapse and mortality.DISCUSSION
In this retrospective study, we reported that CMV repli-
cation after allogeneic HSCT is not an independent variable
for reduced risk of relapse of patients with B cell lymphomas,
but it is associated with lower overall survival and increased
nonrelapse mortality. Pretransplantation disease status and
lymphoma histotype represented the main variables
affecting transplantation outcome, both in terms of relapse
risk and mortality rate.
We conﬁrmed the previousﬁndings that themain variables
associated with relapse risk after HSCT are lymphoma histo-
type,withpatientswithHLandaggressiveNHLhavingahigherultivariate Analysis
Mortality NRM
HR (95% CI) P Value HR (95% CI) P Value
1 1
1.4 (.8-2.4) .2 .3 (.1-.8) .01
.7 (.4-1.3) .4 .2 (.1-.6) .003
.9 (.4-1.9) .8 .6 (.2-1.8) .4
1 1
1.5 (.9-2.6) .08 .8 (.3-1.8) .7
3.1 (1.5-6.5) .001 2.3 (.7-7.1) .1
4.9 (2.8-8.6) <.0001 2.2 (.8-5.5) .1
2.0 (1.3-3.2) .001 2.5 (1.1-5.3) .01
.8 (.3-1.7) .6 1.2 (.2-6.1) .7
1.0 (.7-1.6) .6 2.3 (1.1-4.6) .01
1.6 (1.0-2.6) .03 2.9 (1.1-7.1) .01
remission; PD, progressive disease; HSCT, hematopoietic stem cell trans-
globulin; GVHD, graft-versus-host disease; PB, peripheral blood; BM, bone
aterial and methods. P value with Cox regression analysis.
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lymphoma [23,24], and pretransplantation disease status [25].
This report did not conﬁrm previous encouraging ﬁndings
[7-9] that demonstrated a correlation between CMV repli-
cation and CMV positive serostatus with an anti-AML effect.
On the contrary, the results of our analysis are in line with a
recent publication from Green et al. [9] that did not ﬁnd any
association between CMV replication and relapse risk for
patients with lymphoma or other hematologic malignancies.
Our results extend the ﬁndings of Green et al. [9] to a slightly
larger cohort (265 versus 254), composed only of patients
with B cell lymphomas. Of note, patients with high-risk
disease, such as those with Hodgkin lymphoma, were
much more numerous in our cohort (32%) relative to the
report of the Seattle group (7%). Moreover, our analysis dif-
fers from the one of Green et al. [9] because the variables in
our multivariate models, such as lymphoma histology and
disease status at transplantation, are generally recognized to
be those more strictly associated with the outcome of lym-
phoma patients. Nevertheless, even in this context, we were
not able to observe an independent advantage from CMV
replication on B cell lymphoma relapse. The absence of a so-
called CMV antilymphoma effect is further corroborated by
our other observation that any positive pretransplantation
CMV serostatus was not associated with a lower incidence of
relapse. These data are again in agreement with Green et al.
[9] and with a recent retrospective study from the European
Bone Marrow Transplant Working Group, comprising 16,628
subjects with AML [26].
A potential explanation for the different antitumor effect
observed between AML and lymphoma patients with post-
transplantation CMV replication might be the presence of
different immunologicmechanisms at play in the hematologic
malignancies. Recently, CMV replication was found to induce
the expansion of long-lasting memory-like NKG2Cþ natural
killer cells [27,28] and of gdTcells capable of cross-recognizing
CMVandAMLcells [21].On the contrary, theantitumoractivity
of natural killer cells was found to be more prominent in AML
than in lymphoma cells [29] and gdTcells were not efﬁcacious
against chronic lymphocytic leukemia [30]. Further analyses
are warranted to test whether the B cell lymphoma cells are
less suitable to an immune-mediated effect.
It is important to underscore that, in our study, CMV
replication was conﬁrmed as an independent variable
negatively affecting NRM and OS, as previously described
[31]. In this sense, our ﬁndings suggest to maintain the cur-
rent strategies aimed at limiting CMV replication through
pre-emptive therapy. Besides CMV replication, severe acute
GVHD and chronic GVHD were both associated with higher
NRM, as formerly described.
In conclusion, our ﬁndings conﬁrm lymphoma histotype
and pretransplantation disease status as the main variables
affecting transplantation outcome, whereas post-
transplantation CMV replication and pretransplantation
CMV serostatus are not independent variables affecting the
risk of relapse. Further preclinical studies are required to
better understand whether an immune-mediated effect may
be elicited against B cell lymphoma cells.
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In a multicenter collaboration, we carried out T cellereplete, peripheral blood stem cell (PBSC) trans-
plantations from related, HLA-haploidentical donors with reduced-intensity conditioning (RIC) and post-
transplantation cyclophosphamide (Cy) as graft-versus-host disease (GVHD) prophylaxis in 55 patients
with high-risk hematologic disorders. Patients received 2 doses of Cy 50 mg/kg i.v. on days 3 and 4 after
infusion of PBSC (mean, 6.4  106/kg CD34þ cells; mean, 2.0  108/kg CD3þ cells). The median times to
neutrophil (500/mL) and platelet (>20,000/mL) recovery were 17 and 21 days respectively. All but 2 of the
patients achieved full engraftment. The 1-year cumulative incidences of grade II and grade III acute GVHD
were 53% and 8%, respectively. There were no cases of grade IV GVHD. The 2-year cumulative incidence of
chronic GHVD was 18%. With a median follow-up of 509 days, overall survival and event-free survival at
2 years were 48% and 51%, respectively. The 2-year cumulative incidences of nonrelapse mortality and relapse
were 23% and 28%, respectively. Our results suggest that PBSC can be substituted safely and effectively for
bone marrow as the graft source for haploidentical transplantation after RIC.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hemopoietic stem cell transplantation from
HLA-matched donors is curative in a proportion of patients
with hematologic malignancies, as well as in those with
inherited diseases, such as hemoglobinopathies and bone
marrow failure syndromes. A suitable HLA-identical sibling
donor will be available for about 30% to 35% of patients. For
